Between 20 and 30 percent of people with ADHD do not respond to stimulants or cannot tolerate them. For decades, this group had few alternatives. On July 24, 2026, the US Food and Drug Administration (FDA) approved Simtriyo (centanafadine), a medication developed by Japanese pharmaceutical company Otsuka, as the first drug of an entirely new pharmacological class for ADHD.
The Gap in ADHD Therapy
ADHD ranks among the most common psychiatric disorders in children and adults worldwide. Estimates suggest 5 to 7 percent of school children and 2.5 to 4 percent of adults are affected. The therapeutic backbone for decades: stimulants such as methylphenidate (Ritalin, Concerta) and amphetamine derivatives (Adderall, Vyvanse). These work for most, but a considerable portion remains unresponsive.
According to data from the Add Resource Center, approximately 30 percent of patients respond inadequately to methylphenidate. Contraindications for stimulants also exist in cardiac arrhythmias, uncontrolled hypertension, and certain tic and anxiety disorders. For this group, atomoxetin (Strattera) has been available, functioning as a selective noradrenaline reuptake inhibitor but requiring four to six weeks to take effect. Atomoxetin has been approved in Germany since 2005. Viloxazine (Qelbree), another non-stimulant with different mechanics, has not received EMA approval. This means treatment options for stimulant-intolerant patients in Germany remain particularly limited.
How Centanafadine Differs From Stimulants
Centanafadine is the first approved noradrenaline-dopamine-serotonin reuptake inhibitor (NDSRI) ever. Its mechanism differs from everything previously used in ADHD therapy. The medication simultaneously blocks reuptake of noradrenaline, dopamine, and serotonin without actively releasing them. Stimulants, by contrast, trigger rapid dopamine surges. Physician Patricia Pop, who has clinically analyzed Simtriyo's profile, categorizes centanafadine as substantially noradrenaline-dominant. The noradrenaline transporter occupies 64 to 82 percent, the dopamine transporter approximately 47 percent, and the serotonin transporter 44 percent.
The approval rests on four randomized, double-blind, placebo-controlled Phase 3 trials encompassing children from age 6 (minimum weight 20 kilograms), adolescents, and adults. All four studies met primary efficacy endpoints. In adult studies, improvements on ADHD symptom scales ranged from 2.7 to 5.6 points versus placebo, with measurable effect beginning in week one. The advantage over atomoxetin lies less in effect size than in speed of action onset.
Despite its novel mechanism, the FDA classified Simtriyo as a central nervous system stimulant because abuse potential studies showed relevant properties. The final DEA classification as a controlled substance remained pending at approval. Otsuka announced commercial availability for the second half of 2026. Two boxed warnings accompany the medication. First, in the six-week pediatric study, suicidal thoughts or attempts occurred in 0.7 percent of children receiving centanafadine versus zero in the placebo group. Children and adolescents require close monitoring during treatment. Second, standard warnings apply regarding controlled substances and potential for abuse and addiction.
Context: How Rare New ADHD Mechanisms Are
To contextualize this approval, one must understand how rarely truly new mechanisms appear in ADHD therapy. Until 2002, only stimulants existed. In November 2002, the FDA approved atomoxetin (Strattera) by Eli Lilly as the first non-stimulant, a watershed moment for patients without stimulant options. Response rates range from 55 to 64 percent in children and 40 to 56 percent in adults, appearing modest by current stimulant comparison.
In 2021, viloxazine (Qelbree) entered the US market initially for children and adolescents ages 6 to 17. Adult approval followed in April 2022. It inhibits noradrenaline reuptake and acts as a partial serotonin agonist. Clinical advantage over atomoxetin: no CYP2D6 metabolism, meaning fewer interactions with frequently prescribed antidepressants like fluoxetine. Cost without insurance: 360 to 530 US dollars monthly. Viloxazine remains unapproved in Germany.
Centanafadine now adds a third mechanism. It metabolizes via monoamine oxidase A, not CYP2D6. This means fluoxetine and paroxetine, frequently used in ADHD patients with comorbid depression, do not reduce centanafadine levels, as occurs with atomoxetin. Whether this pharmacological difference carries clinical relevance will emerge in practice.
Three Hurdles Until Pharmacy Shelves
Whether Simtriyo closes the treatment gap for stimulant-intolerant ADHD patients depends on three factors.
First, DEA classification. Without completed controlled substance designation, the medication cannot appear on pharmacy shelves. Otsuka announced 2026 market entry but has not specified a quarter.
Second, insurance coverage. US health insurers typically require documented attempts with cheaper generics before reimbursing newer medications. For patients with medical contraindications against stimulants, this documentation is burdensome. Comparable medications like Qelbree cost 360 to 530 US dollars monthly without insurance.
Third, international approval. No European Medicines Agency (EMA) decision is pending. When and whether Simtriyo becomes available in Germany remains open. For German patients for whom neither stimulants nor atomoxetin works, therapeutic options thus remain unchanged for now.